- Theralase Technologies (TSXV:TLT) initiated Good Laboratory Practice toxicology analysis of Rutherrin, its intravenously delivered drug designed to target and destroy cancer cells.
- Initial results, expected by early 2027, would allow the company to seek regulatory approval to test the drug’s encouraging preclinical findings in first-in-human trials.
- Theralase Technologies stock last traded at C$0.18 and has given back 14.29 per cent since 2021.
Theralase Technologies (TSXV:TLT) initiated Good Laboratory Practice toxicology analysis of Rutherrin, its intravenously delivered drug designed to target and destroy cancer cells.
The drug, a combination of the small molecule, Ruvidar, and transferrin, a blood plasma protein made by the liver to deliver iron throughout the body, has accumulated a considerable amount of preclinical evidence in support of its oncological benefit, most recently in the area of muscle-invasive bladder cancer (MIBC).
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
GLP analysis will advance Rutherrin a step towards first-in-human trials by determining optimal dosing for glio blastoma multiforme (GBM), an often fatal form of brain cancer, non-small cell lung cancer (NSCLC), the leading cause of cancer death across the world, and MIBC, which represents 25% of all bladder cancer diagnoses. According to Tuesday’s news release, the company plans to expand the study to pancreatic and colorectal cancer thereafter.
Upon successful toxicology reports and regulatory approval, Theralase will kick off a clinical development program to determine how well Rutherrin embeds itself within tumours tied to these cancers, potentially opening the door to multiple administrations, an evaluation of safety, efficacy and tolerability, both with and without standard of care treatments, as well as potential partnerships and licensing agreements to bring a go-to-market strategy clearer into view.
Initial GLP results are expected by early 2027.
Leadership commentary
“Our scientific team has generated an extensive body of preclinical research demonstrating Rutherrin’s potential across numerous life-threatening cancers,” Arkady Mandel, Chief Scientific Officer of Theralase Technologies, said in a statement. “I am delighted that after years of research, Theralase is now in the position to commence GLP toxicology analysis for the intravenous administration of Rutherrin. Pending successful completion of this analysis, the company is laser-focused on the clinical development of this technology for: GBM, NSCLC, MIBC and many other deadly and/or hard-to-treat cancers.”
About Theralase Technologies
Theralase is a clinical-stage pharmaceutical company developing energy-activated small molecules that destroy cancer, bacteria and viruses.
Theralase Technologies stock (TSXV:TLT) last traded at C$0.18 and has given back 14.29 per cent since 2021.
Join the discussion: Find out what investors are saying about this healthcare stock on the Theralase Technologies Inc. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
